Calaspargase pegol
- Generic Name
- Calaspargase pegol
- Brand Names
- Asparlas
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 941577-06-6
- Unique Ingredient Identifier
- T9FVH03HMZ
- Background
Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , .
...
- Indication
This drug is is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years .
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Associated Therapies
- -
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06561074
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: Calaspargase pegolDrug: VenetoclaxDrug: BortezomibDrug: DasatinibDrug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: NelarabineDrug: MethotrexateDrug: Thioguanine
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 145
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: Asparaginase Erwinia chrysanthemiProcedure: Bone Marrow AspirationProcedure: Computed TomographyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: PrednisoloneDrug: DexamethasoneDrug: PrednisoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyDrug: LeucovorinProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT06317662
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
Phase 2
Withdrawn
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Computed TomographyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanBiological: NavitoclaxDrug: PegaspargaseDrug: NelarabineProcedure: Positron Emission TomographyDrug: ThioguanineProcedure: X-Ray ImagingDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DaunorubicinDrug: DoxorubicinProcedure: EchocardiographyDrug: LeucovorinDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: PrednisoloneDrug: PrednisoneDrug: VincristineRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Phase 2
Recruiting
- Conditions
- Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Calaspargase PegolProcedure: EchocardiographyDrug: Fludarabine PhosphateDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PrednisoloneDrug: PrednisoneDrug: RevumenibDrug: Vincristine Sulfate
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT05761171
- Locations
- 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 440
- Registration Number
- NCT05602194
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Presbyterian Hospital, Albuquerque, New Mexico, United States
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 20
- Registration Number
- NCT05581030
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1
Recruiting
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
Phase 1
Active, not recruiting
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath